Cancer means that Barnes, who turns 80 on Jan. 19, will spend the rest of his life on chemotherapy drugs. Still, he says, he doesn't grieve for his aging and ailing body. "We are these creatures who come into this earth unbidden, not consulted, and we live a certain amount of time much longer than our ancestors," he says. "But because we live longer, our body begins to break down and the medical costs increase."
“The unimaginable has happened,” “My beautiful husband has been taken from us. The light of my life. I was the luckiest to be loved and adored by you Jamie. I love you endlessly, not just now, but eternally.”
I first ran the marathon in 2018 with a friend of mine, and I ran it again in 2023 with my brother, Larkin said. In 2024, I was diagnosed with ovarian cancer, and decided after I had this major operation and gone through chemo that I was gonna show up and run. In 2025, my cancer came back. Larkin's diagnosis has been an extensive challenge both physically and mentally.
I'll be here for a while right now. We're between cycles. They started the hardcore chemo on the PICC line last week. I had a 10-day cycle on Sunday, which made watching football a blast, Papa said, pointing out an IV in his arm. I got a little break between Cycle A and Cycle B. I will be with you as many days as I can.
In a wholly new approach to cancer treatment, Northwestern University biomedical engineers have doubled the effectiveness of chemotherapy in animal experiments. Instead of attacking cancer directly, the first-of-its-kind strategy prevents cancer cells from evolving to withstand treatment - making the disease easier to target with existing drugs. Not only did the approach fully wipe out the disease to near completion in cellular cultures, but it also dramatically increased the effectiveness of chemotherapy in mouse models of human ovarian cancer.
In our original article, we identified a key issue in the visualization of metabolite concentrations. Specifically, values below 100 ng/ml were wrongly formatted, which impacted figures.
